|CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment|
Y Jin, Z Desta, V Stearns, B Ward, H Ho, KH Lee, T Skaar, AM Storniolo, ...
Journal of the National Cancer Institute 97 (1), 30-39, 2005
|Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment|
S Borges, Z Desta, L Li, TC Skaar, BA Ward, A Nguyen, Y Jin, ...
Clinical Pharmacology & Therapeutics 80 (1), 61-74, 2006
|Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate|
R Arora, MO Koch, JN Eble, TM Ulbright, L Li, L Cheng
Cancer: Interdisciplinary International Journal of the American Cancer …, 2004
|Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant|
M Fan, PS Yan, C Hartman-Frey, L Chen, H Paik, SL Oyer, JD Salisbury, ...
Cancer research 66 (24), 11954-11966, 2006
|Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer|
NL Henry, F Azzouz, Z Desta, L Li, AT Nguyen, S Lemler, J Hayden, ...
Journal of Clinical Oncology 30 (9), 936, 2012
|Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro|
Z Desta, T Saussele, B Ward, J Blievernicht, L Li, K Klein, DA Flockhart, ...
Future Medicine Ltd 8 (6), 547-558, 2007
|Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate|
C Sweeney, L Li, R Shanmugam, P Bhat-Nakshatri, V Jayaprakasan, ...
Clinical Cancer Research 10 (16), 5501-5507, 2004
|Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors|
NL Henry, JT Giles, D Ang, M Mohan, D Dadabhoy, J Robarge, J Hayden, ...
Breast cancer research and treatment 111 (2), 365-372, 2008
|Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans|
Z Wang, SD Hall, JF Maya, L Li, A Asghar, JC Gorski
British journal of clinical pharmacology 55 (1), 77-85, 2003
|Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells|
YC Lim, L Li, Z Desta, Q Zhao, JM Rae, DA Flockhart, TC Skaar
Journal of Pharmacology and Experimental Therapeutics 318 (2), 503-512, 2006
|A community computational challenge to predict the activity of pairs of compounds|
M Bansal, J Yang, C Karan, MP Menden, JC Costello, H Tang, G Xiao, ...
Nature biotechnology 32 (12), 1213, 2014
|A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer|
F Fang, C Balch, J Schilder, T Breen, S Zhang, C Shen, L Li, ...
Cancer 116 (17), 4043-4053, 2010
|Association of polymorphisms of angiogenesis genes with breast cancer|
BP Schneider, M Radovich, GW Sledge, JD Robarge, L Li, AM Storniolo, ...
Breast cancer research and treatment 111 (1), 157-163, 2008
|Prognostic DNA methylation biomarkers in ovarian cancer|
SH Wei, C Balch, HH Paik, YS Kim, RL Baldwin, S Liyanarachchi, L Li, ...
Clinical Cancer Research 12 (9), 2788-2794, 2006
|Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients|
S Borges, Z Desta, Y Jin, A Faouzi, JD Robarge, S Philip, A Nguyen, ...
The Journal of Clinical Pharmacology 50 (4), 450-458, 2010
|Variability of heart rate correction methods for the QT interval|
M Desai, L Li, Z Desta, M Malik, D Flockhart
British journal of clinical pharmacology 55 (6), 511-517, 2003
|Loss of 14-3-3σ in prostate cancer and its precursors|
L Cheng, CX Pan, JT Zhang, S Zhang, MS Kinch, L Li, LA Baldridge, ...
Clinical cancer research 10 (9), 3064-3068, 2004
|Association between the CYP3A5 genotype and blood pressure|
H Ho, A Pinto, SD Hall, DA Flockhart, L Li, TC Skaar, P Cadman, ...
Hypertension 45 (2), 294-298, 2005
|Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions|
JD Duke, X Han, Z Wang, A Subhadarshini, SD Karnik, X Li, SD Hall, ...
PLoS computational biology 8 (8), 2012
|Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin|
SK Quinney, X Zhang, A Lucksiri, JC Gorski, L Li, SD Hall
Drug metabolism and disposition 38 (2), 241-248, 2010